RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy. (RESOLVE-AF)
Prospective, Single Arm, Multi-center, Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-pulmonary Vein Sources of Atrial Fibrillation and Guide Ablation Therapy.
Sponsor: Ablacon, Inc.
A NA clinical study on Arrhythmia and Arrhythmias, Cardiac, this trial is ongoing. The trial is conducted by Ablacon, Inc. and has accumulated 11 data snapshots since 2023. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting NA
-
May 2025 — Sep 2025 [monthly]
Active Not Recruiting NA
-
Mar 2025 — May 2025 [monthly]
Active Not Recruiting NA
-
Jan 2025 — Mar 2025 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Nov 2024 — Jan 2025 [monthly]
Recruiting NA
▶ Show 6 earlier versions
-
Sep 2024 — Nov 2024 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Mar 2024 — Jul 2024 [monthly]
Recruiting NA
-
Jan 2024 — Mar 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Oct 2023 — Jan 2024 [monthly]
Not Yet Recruiting NA
-
Jul 2023 — Oct 2023 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ablacon, Inc.
- Cortex
For direct contact, visit the study record on ClinicalTrials.gov .